Policy Brief

Issue No. 26

Rare diseases – Talk of the Town for Some Time but What’s Next?

By : Phornnaphat Chertchinnapa, Annapoorna Prakash

Issue No. 25

South Korea’s Experience of Reimbursing High-Cost Medicines

By : Dr. Dimple Butani

Issue No. 24

Experience in Using HTA for Expanding UHC Benefit Package to Cover Rare Diseases and High-Cost Drugs among Seven Middle and High-Income Countries: A targeted literature review

By : Kumaree Pachanee, Dian Faradiba

Issue No. 149

Health Financing during COVID-19 responses in Thailand

By : Papada Ranron, Praewa Kulatnam, Aungsumalee Pholpark, Sikarn lssarachaiyos

Issue No. 23

Learning from Cancer Drug Fund (CDF) in England: A special reimbursement pathway for high-cost cancer drugs

By : Dian Faradiba

Issue No. 145

Unpacking Digital Health: A breakdown of concepts and definitions

By : Dr. Dimple Butani

Issue No. 142

High-Cost Users Still Came to Hospitals During the COVID-19 Pandemic in Thailand

By : Wanrudee Isaranuwatchai, PhD, Picharee Karunayawong, Dr. Piyada Gaewkhiew, Chulathip Boonma, Myka Harun Sarajan

Issue No. 121

Distributing ‘Smart Watch’ alone cannot reduce Sedentary Behavior. An Active Lifestyle can be encouraged by harmonizing Individual, Social, Organizational, and Environmental levels.

By : Katika Akksilp, M.D.

Issue No. 99

Preliminary recommendations on the establishment of a regional centre for infectious disease control in ASEAN

By : Yot Teerawattananon, PhD., Manit Sittimart, Aparna Ananthakrishnan

Issue No. 20

Which investment on interventions against COVID-19 pandemic is worth its cost?

By : Amanuel Yigezu, Mezgebu Yitayal, Alemnesh H. Mirkuzie, Zekarias Getu, Alemayehu Hailu

Antimicrobial Resistance Policy in Thailand

By : Chris Painter, Aparna Ananthakrishnan

Issue No. 19

Addressing Antimicrobial Resistance in Thailand: A Policy Overview

By : Chris Painter, Aparna Ananthakrishnan